Habbick B, Baker M J, McNutt M, Cockcroft D W
Department of Community Health and Epidemiology, Royal University Hospital, Saskatoon SK.
CMAJ. 1995 Nov 15;153(10):1437-43.
To examine recent trends in the use of inhaled beta 2-adrenergic agonists and inhaled corticosteroids for the treatment of asthma among Saskatchewan residents and to determine whether these trends are in keeping with widely publicized guidelines recommending a reduction in the use of agents to treat symptoms (i.e., inhaled beta 2-adrenergic agonists) and increased use of prophylactic agents (i.e., inhaled corticosteroids).
Descriptive pharmacoepidemiologic study conducted with the use of data from the computerized database of the Saskatchewan Prescription Drug Plan.
Saskatchewan.
Saskatchewan residents 5 to 54 years of age who received one or more outpatient prescriptions for drugs to treat asthma (inhaled drugs, ingested beta 2-adrenergic agonists and ingested methylxanthines) from 1989 to 1993.
Epidemiologic trends, calculated for each year: number of prescriptions per 1,000 persons; number of patients who received prescriptions for inhaled corticosteroids, inhaled beta 2-adrenergic agonists and any type of drug to treat asthma; mean number of such prescriptions per patient; and weighted mean amount of salbutamol, fenoterol and beclomethasone dispensed per patient.
There has been an increase in the proportion of the population receiving prescriptions for drugs to treat asthma. The number of patients receiving these drugs per 1,000 people rose during the study period from 33.38 to 46.59 for any drug to treat asthma, from 24.70 to 33.77 for inhaled beta 2-adrenergic agonists and from 6.1 to 19.9 for inhaled corticosteroids. The mean number of prescriptions per patient decreased steadily for all drugs to treat asthma (from 5.34 in 1989 to 3.88 in 1993), for inhaled beta 2-adrenergic agonists (from 4.35 to 3.09) and for inhaled corticosteroids (from 2.98 to 2.25). The weighted mean amount of inhaled salbutamol dispensed per patient per year decreased by 40%, from 178.08 mg in 1989 to 109.14 mg in 1993. The weighted amount of fenoterol dispensed per patient per year declined even more, by 58%, from 387.91 mg in 1989 to 164.00 mg in 1993. Conversely, the weighted amount of inhaled beclomethasone dispensed per patient per year increased by 35% from 46.95 mg in 1989 to 63.50 mg in 1992, then dropped to 56.17 mg per year in 1993.
These data demonstrate a substantial change in Saskatchewan in the prescribing of drugs to treat asthma; they suggest that many physicians responded to current guidelines advocating increased attention to prevention of airway inflammation in the treatment of asthma.
研究萨斯喀彻温省居民使用吸入型β2肾上腺素能激动剂和吸入型糖皮质激素治疗哮喘的近期趋势，并确定这些趋势是否符合广为宣传的指南，即减少用于治疗症状的药物（即吸入型β2肾上腺素能激动剂）的使用，并增加预防性药物（即吸入型糖皮质激素）的使用。
利用萨斯喀彻温省处方药计划计算机数据库中的数据进行描述性药物流行病学研究。
萨斯喀彻温省。
1989年至1993年期间，年龄在5至54岁之间、接受过一种或多种治疗哮喘药物（吸入药物、口服β2肾上腺素能激动剂和口服甲基黄嘌呤）门诊处方的萨斯喀彻温省居民。
每年计算的流行病学趋势：每1000人的处方数；接受吸入型糖皮质激素、吸入型β2肾上腺素能激动剂和任何类型哮喘治疗药物处方的患者人数；每位患者此类处方的平均数量；以及每位患者沙丁胺醇、非诺特罗和倍氯米松的加权平均配药量。
接受哮喘治疗药物处方的人群比例有所增加。在研究期间，每1000人中接受这些药物治疗的患者人数，对于任何哮喘治疗药物从33.38增至46.59，对于吸入型β2肾上腺素能激动剂从24.70增至33.77，对于吸入型糖皮质激素从6.1增至19.9。所有哮喘治疗药物每位患者的平均处方数稳步下降（从1989年的5.34降至1993年的3.88），吸入型β2肾上腺素能激动剂（从4.35降至3.09），吸入型糖皮质激素（从2.98降至2.25）。每位患者每年沙丁胺醇的加权平均配药量下降了40%，从1989年的178.08毫克降至1993年的109.14毫克。每位患者每年非诺特罗的配药量下降幅度更大，为58%，从1989年的387.91毫克降至1993年的164.00毫克。相反，每位患者每年吸入型倍氯米松的配药量从1989年的46.95毫克增加了35%，至1992年为63.50毫克，但在1993年降至每年56.17毫克。
这些数据表明，萨斯喀彻温省在哮喘治疗药物的处方方面发生了重大变化；这表明许多医生响应了当前提倡在哮喘治疗中更加关注预防气道炎症的指南。
